1530 Stock Overview
3SBio Inc. researches, develops, manufactures, markets, and sells biopharmaceutical products in the People’s Republic of China.
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$6.67|
|52 Week High||HK$12.30|
|52 Week Low||HK$6.16|
|1 Month Change||-6.32%|
|3 Month Change||-22.44%|
|1 Year Change||-12.58%|
|3 Year Change||-44.69%|
|5 Year Change||-14.49%|
|Change since IPO||-28.66%|
Recent News & Updates
An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 50% Undervalued
Does the November share price for 3SBio Inc. ( HKG:1530 ) reflect what it's really worth? Today, we will estimate the...
We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
|1530||HK Biotechs||HK Market|
Return vs Industry: 1530 underperformed the Hong Kong Biotechs industry which returned 23.2% over the past year.
Return vs Market: 1530 underperformed the Hong Kong Market which returned -5.2% over the past year.
|1530 Average Weekly Movement||4.9%|
|Biotechs Industry Average Movement||7.9%|
|Market Average Movement||6.8%|
|10% most volatile stocks in HK Market||13.3%|
|10% least volatile stocks in HK Market||3.3%|
Stable Share Price: 1530 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 1530's weekly volatility (5%) has been stable over the past year.
About the Company
3SBio Inc. researches, develops, manufactures, markets, and sells biopharmaceutical products in the People’s Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; EPIAO and SEPO recombinant human erythropoietins to treat anemia; and Cipterbin for HER2-positive metastatic breast cancer in combination with chemotherapy. It also offers Mandi to treat male alopecia and alopecia areata; Xenopax for preventing acute rejection after renal transplant; Byetta for the glycemic control in patients with type 2 diabetes; Qiming Keli to treat retinopathy caused by type 2 diabetic; Aiyishu for iron-deficiency anemia; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis.
3SBio Fundamentals Summary
|1530 fundamental statistics|
Is 1530 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|1530 income statement (TTM)|
|Cost of Revenue||CN¥1.10b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.41|
|Net Profit Margin||17.20%|
How did 1530 perform over the long term?See historical performance and comparison
Is 3SBio undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 1530 (HK$6.67) is trading below our estimate of fair value (HK$13.46)
Significantly Below Fair Value: 1530 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 1530's PE Ratio (13.3x) is in line with the Hong Kong Biotechs industry average.
PE vs Market: 1530 is poor value based on its PE Ratio (13.3x) compared to the Hong Kong market (9.3x).
Price to Earnings Growth Ratio
PEG Ratio: 1530 is poor value based on its PEG Ratio (1.7x)
Price to Book Ratio
PB vs Industry: 1530 is good value based on its PB Ratio (1.2x) compared to the HK Biotechs industry average (4.3x).
How is 3SBio forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1530's forecast earnings growth (7.7% per year) is above the savings rate (1.5%).
Earnings vs Market: 1530's earnings (7.7% per year) are forecast to grow slower than the Hong Kong market (17.7% per year).
High Growth Earnings: 1530's earnings are forecast to grow, but not significantly.
Revenue vs Market: 1530's revenue (7.6% per year) is forecast to grow slower than the Hong Kong market (12.5% per year).
High Growth Revenue: 1530's revenue (7.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1530's Return on Equity is forecast to be low in 3 years time (10.7%).
How has 3SBio performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1530 has high quality earnings.
Growing Profit Margin: 1530's current net profit margins (17.2%) are lower than last year (25.2%).
Past Earnings Growth Analysis
Earnings Trend: 1530's earnings have grown by 8.3% per year over the past 5 years.
Accelerating Growth: 1530's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 1530 had negative earnings growth (-23.8%) over the past year, making it difficult to compare to the Biotechs industry average (51.1%).
Return on Equity
High ROE: 1530's Return on Equity (6.9%) is considered low.
How is 3SBio's financial position?
Financial Position Analysis
Short Term Liabilities: 1530's short term assets (CN¥7.4B) exceed its short term liabilities (CN¥1.3B).
Long Term Liabilities: 1530's short term assets (CN¥7.4B) exceed its long term liabilities (CN¥3.1B).
Debt to Equity History and Analysis
Debt Level: 1530 has more cash than its total debt.
Reducing Debt: 1530's debt to equity ratio has reduced from 57.6% to 18.4% over the past 5 years.
Debt Coverage: 1530's debt is well covered by operating cash flow (55.6%).
Interest Coverage: 1530 earns more interest than it pays, so coverage of interest payments is not a concern.
What is 3SBio current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 1530's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 1530's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 1530's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 1530's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: 1530 is not paying a notable dividend for the Hong Kong market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 1530's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jing Lou (58 yo)
Dr. Jing Lou, M.D., Ph.D. is a Co-Founder of 3SBio Inc. and has been its Executive Chairman of the Board since April 1, 2012 and also serves as its Chief Executive Officer and President. Dr. Lou served as...
CEO Compensation Analysis
Compensation vs Market: Jing's total compensation ($USD611.20K) is about average for companies of similar size in the Hong Kong market ($USD527.57K).
Compensation vs Earnings: Jing's compensation has been consistent with company performance over the past year.
Experienced Management: 1530's management team is seasoned and experienced (5.6 years average tenure).
Experienced Board: 1530's board of directors are considered experienced (6.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
3SBio Inc.'s employee growth, exchange listings and data sources
- Name: 3SBio Inc.
- Ticker: 1530
- Exchange: SEHK
- Founded: 1993
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$16.824b
- Shares outstanding: 2.52b
- Website: https://www.3sbio.com
Number of Employees
- 3SBio Inc.
- No. 3 A1, Road 10
- Shenyang Economy and Technology Developm
- Liaoning Province
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/11/30 10:05|
|End of Day Share Price||2021/11/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.